Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer

References

• American Cancer Society’s. What are the key statistics about breast cancer. Available from: http://www.mbcn.org/incidence-and-incidence-rates/
   Google Scholar
• Bhoo-Pathy N, Yip CH, Hartman M, et al. Breast cancer research in Asia: adopt or adapt Western knowledge? Eur J Cancer. 2013;49(3):703–709.
   PubMed Web of Science ®Google Scholar
• Lang HC, Chen HW, Chiou TJ, et al. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan. J Med Econ. 2016;19(10):923–927.
   PubMed Web of Science ®Google Scholar
• Aboutorabi A, Hadian M, Ghaderi H, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. Glob J Health Sci. 2014;7(1):98–106.
   PubMedGoogle Scholar
• Chen W, Jiang Z, Shao Z, et al. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12(Suppl 3):S82–4.
   PubMed Web of Science ®Google Scholar
• Buendía JA, Vallejos C, Pichón-Rivière A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013;33(3):411–417.
   PubMed Web of Science ®Google Scholar
• Millar JA, Millward MJ. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmacoeconomics. 2007;25(5):429–442.
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Molino A, Fiorio E, et al. Relapse rate after adjuvant trastuzumab in the northeast of Italy: preliminary data from a multicenter observational study in a clinical setting. J Clin Oncol. 2012;30:15, suppl;abstract 586
   Web of Science ®Google Scholar
• Mustacchi G, Biganzoli L, Pronzato P, et al. HER2-positive metastatic breast cancer: a changing scenario. Crit Rev Oncol Hematol. 2015;95(1):78–87.
   PubMed Web of Science ®Google Scholar
• Krell J, James CR, Shah D, et al. Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome. Clin Breast Cancer. 2011 June;11(3):153–160.
   PubMed Web of Science ®Google Scholar
• Vaz Duarte Luis IM, Ottesen RA, Hughes ME. Impact of hormone receptor (HR) status on clinicopathological features, patterns of recurrence, and clinical outcomes among patients (pts) with human epidermal growth factor receptor-2 positive (HER2) breast cancer (BC) in the National Comprehensive Cancer Network (NCCN). J Clin Oncol. 2012;30(suppl); abstr 599.
   Google Scholar
• Dall P, Lenzen G, Goehler T, et al., Trastuzumab treatment of early breast cancer: long-term results from a prospective observation study, including a large cohort of elderly patients. In: 36th Annual SABCS; 2013. ( [Abs P2-15-02]). J Geriatr Oncol 2015;6(6):462-469.
   Google Scholar
• Kümler I, Tuxen MK, Nielsen DL. A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev. 2014;40(2):259–270.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Beckmann MW, Rody A, et al. HER2 dimerization inhibitor pertuzumab - mode of action and clinical data in breast cancer. Breast Care (Basel). 2013;8(1):49–55.
   PubMed Web of Science ®Google Scholar
• Gerratana L, Bonotto M, Bozza C, et al. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. Expert Opin Biol Ther. 2017;17(3):365–374.
   PubMed Web of Science ®Google Scholar
• Bianchini G, Pusztai L, Pienkowski T, et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol. 2015;26:2429–2436.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–734.
   PubMed Web of Science ®Google Scholar
• Baselga J, Cortés J, Kim S-B, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–119.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278–2284.
   PubMed Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.
   PubMed Web of Science ®Google Scholar
• Attard CL, Pepper AN, Brown ST, et al. Cost effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ. 2015;18:173–188.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–251.
   PubMed Web of Science ®Google Scholar
• Statistics times: International Monetary Fund World Economic Outlook (April-2015). [cited 2017 Jan 24]. Available from: http://statisticstimes.com/economy/projected-world-gdp-capitaranking.php
   Google Scholar
• Directorate-General of Budget, Accounting and Statistics Ministry of Foreign Affairs, Republic of China (Taiwan). [cited 2017 Jan 24]. Available from: http://taiwantoday.tw/ct.asp?xItem=239566&ctNode=435
   Google Scholar
• Leung HW, Chan AL, Muo CH, et al. Cost-effectiveness of gemcitabine plus modern radiotherapy in locally advanced pancreatic cancer. Clin Ther. 2016;38(5):1174–1183.
   PubMed Web of Science ®Google Scholar
• Petrou PK, Talias MA. Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus. Expert Rev Pharmacoecon Outcomes Res. 2014;14:131–138.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Martikainen JA, Soini EJ, et al. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther. 2008;30:382–392.
   PubMed Web of Science ®Google Scholar
• Hedden L, O’Reilly S, Lohrisch C, et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist. 2012;17:164–171.
   PubMed Web of Science ®Google Scholar
• Durkee BY, Qian Y, Pollom EL, et al. Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2016;34(9):902–909.
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Ali AA, et al. Cost- effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positivemetastatic breast cancer in the United States. Breast Cancer ResTreat. 2016;160(1):187–196.
   PubMed Web of Science ®Google Scholar
• National Centre for Pharmacoeconomics. Cost effectiveness of pertuzumab (perjeta) in combination with trastuzumab and docetaxel in adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 Therapy or chemotherapy. Dublin 8 (Ireland): National Centre for Pharmacoeconomics, Rialto Gate, St. James’s Hospital, 2013. http://www.ncpe.ie/wp-content/uploads/2013/08/Web-summary-pertuzumab2.pdf
   Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–1641.
   PubMed Web of Science ®Google Scholar
• Dilla T, Lizan L, Paz S, et al. Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. Patient Prefer Adherence. 2015;10:1–7.
   PubMed Web of Science ®Google Scholar
• Robert NJ, Goertz HP, Chopra P, et al. HER2-positive metastatic breast cancer patients receiving pertuzumab in a community oncology practice setting: treatment patterns and outcomes. Drugs Real World Outcomes. 2017;4(1):1–7.
   PubMedGoogle Scholar
• Mustacchi G, Generali D. Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs. J Med Econ. 2017;4:405–408.
   PubMed Web of Science ®Google Scholar